MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Cisplatin (Platinol ®)

A Phase I Trial of Surgical Resection and Intraoperative Hyperthermic Cisplatin and Gemcitabine for Pleural Mesothelioma

Journal of Thoracic Oncology 2018 May 3 [Link] Burt BM, Richards WG, Lee HS, Bartel S, Dasilva MC, Gill RR, Jaklitsch MT, Johnson BE, Swanson SJ, Bueno R, Sugarbaker DJ Abstract INTRODUCTION: The primary objective of this single-institution Phase I clinical trial was to establish the maximum tolerated dose (MTD) of gemcitabine added to cisplatin […]

Comments Off on A Phase I Trial of Surgical Resection and Intraoperative Hyperthermic Cisplatin and Gemcitabine for Pleural Mesothelioma

Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma

Lung Cancer [Epub March 2018] [Link] Kopecka J, Salaroglio IC, Righi L, Libener R, Orecchia S, Grosso F, Milosevic V, Ananthanarayanan P, Ricci L, Capelletto E, Pradotto M, Napoli F, Di Maio M, Novello S, Rubinstein M, Scagliotti GV, Riganti C Abstract OBJECTIVES: Cisplatin-based chemotherapy is moderately active in malignant pleural mesothelioma (MPM) due to […]

Comments Off on Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma

Nintedanib is active in malignant pleural mesothelioma cell models and inhibits angiogenesis and tumor growth in vivo

Clinical cancer research 2018 May 3 [Link] Laszlo V, Valko Z, Kovacs I, Ozsvar J, Hoda MA, Klikovits T, Lakatos D, Czirók A, Garay T, Stiglbauer A, Helbich TH, Groger M, Tovari J, Klepetko W, Pirker C, Grusch M, Berger W, Hilberg F, Hegedus B, Dome B Abstract PURPOSE: Malignant pleural mesothelioma (MPM) is an […]

Comments Off on Nintedanib is active in malignant pleural mesothelioma cell models and inhibits angiogenesis and tumor growth in vivo

Putative cancer stem cells may be the key target to inhibit cancer cell repopulation between the intervals of chemoradiation in murine mesothelioma.

BMC Cancer 2018 April [Link] Wu L, Blum W, Zhu CQ, Yun Z, Pecze L, Kohno M, Chan ML, Zhao Y, Felley-Bosco E, Schwaller B, de Perrot M. Abstract BACKGROUND: Cancer cell repopulation during chemotherapy or radiotherapy is a major factor limiting the efficacy of treatment. Cancer stem cells (CSC) may play critical roles during […]

Comments Off on Putative cancer stem cells may be the key target to inhibit cancer cell repopulation between the intervals of chemoradiation in murine mesothelioma.

Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for the treatment of malignant mesothelioma.

BMC Cancer 2018 April [Link] Giger-Pabst, Demtröder, Falkenstein, Ouaissi, Götze, Rezniczek, Tempfer Abstract BACKGROUND: Patients with recurrent malignant epithelioid mesothelioma (MM) after surgery and standard chemotherapy with cisplatin and pemetrexed have limited treatment options. METHODS: We performed a retrospective cohort study of patients with recurrent MM undergoing Pressurized IntraPeritoneal/Thoracal Aerosol Chemotherapy (PIPAC/PITAC) with doxorubicin 1.5 mg/m2 and cisplatin 7.5 mg/m2. […]

Comments Off on Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for the treatment of malignant mesothelioma.

Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression

Frontiers in Oncology 2018 Februrary [Link] Oehl K et. al. Abstract Experimental models closely representing in vivo conditions allow investigating mechanisms of resistance. Our aims were to establish a live-cell biobank of malignant pleural mesothelioma (MPM) samples and to obtain proof of principle that primary culture chemoresistant models, mimicking tumor progression observed in patients, can […]

Comments Off on Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression

Aminopeptidase N/CD13 as a Potential Therapeutic Target in Malignant Pleural Mesothelioma

The European Respiratory Journal [Epub ahead of print] [Link] Otsuki T et. al. Abstract Angiogenesis is a crucial factor in the progression of malignant pleural mesothelioma (MPM), and antiangiogenic strategies might be effective against MPM. Aminopeptidase N/CD13 (APN/CD13) promotes tumour angiogenesis and is associated with poor prognosis; however, its clinical significance in MPM remains unclear.In […]

Comments Off on Aminopeptidase N/CD13 as a Potential Therapeutic Target in Malignant Pleural Mesothelioma

Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression

Frontiers in Oncology 2018 February [Link] Oehl K, Kresoja-Rakic J, Opitz I, Vrugt B, Weder W, Stahel R, Wild P, Felley-Bosco E Abstract Experimental models closely representing in vivo conditions allow investigating mechanisms of resistance. Our aims were to establish a live-cell biobank of malignant pleural mesothelioma (MPM) samples and to obtain proof of principle […]

Comments Off on Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression

A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma

BMC Cancer 2018 February 17 [Link] de Fonseka D, Arnold DT, Stadon L, Morley A, Keenan E, Darby M, Armstrong L, Virgo P, Maskell NA Abstract BACKGROUND: Radiological monitoring of malignant pleural mesothelioma (MPM) using modified RECIST criteria is limited by low sensitivity and inter-observer variability. Serial serum mesothelin measurement has shown utility in the […]

Comments Off on A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma

Current Management and Future Opportunities for Peritoneal Metastases: Peritoneal Mesothelioma

Annals of Surgical Oncology 2018 February [Epub ahead of print] [Link] Alexander HR Jr., Li CY, Kennedy TJ Abstract PURPOSE: Diffuse malignant peritoneal mesothelioma (MPM) is a rare and ultimately fatal cancer that was first described just over a century ago. It is a diffuse malignancy arising from the mesothelial lining of the peritoneum; morbidity […]

Comments Off on Current Management and Future Opportunities for Peritoneal Metastases: Peritoneal Mesothelioma